Clinical Trial Update: An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial update for SPX-101 inhalation solution in cystic fibrosis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• SPX-101 (SPX-101)

Snippet

Sponsor: Spyryx Biosciences, Inc. | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2019-12-30